Medicinal Chemistry Journal of Medicinal Chemistry (ACS)
Branched acyl-lysine peptides turn SIRT2 substrates into slow-turnover inhibitors that work in cells
- Peptides bearing methyl-branched or cyclopropyl-modified acyl groups on lysine inhibit SIRT2 potently, lingering on the enzyme with almost no turnover, as expected for slow substrates.
- Crystal structures with NAD+ show a competent but unproductive enzyme state, and comparison with SIRT1 and SIRT3 reveals isoform-specific acyl-chain paths behind selectivity.
- Optimized peptides engage SIRT2 in cells and raise alpha-tubulin acetylation.
Is this really inhibition or just a substrate the enzyme chews through slowly? The cell data suggest the former, but I'd want the thioacylation intermediate shown directly and a deacylase-dead SIRT2 control. Peptides still carry permeability and stability baggage, so the next step is a macrocyclic or peptidomimetic version, benchmarked against SirReal-type and thiomyristoyl inhibitors.
Paper: Journal of Medicinal Chemistry (ACS) ↗ Alkyl-Branched Acyl-Lysine Peptides as Potent Cell-Permeable Slow-Substrate Inhibitors of SIRT2